CD274 and esophageal squamous cell carcinoma: Since then, the FDA has proved PD-L1 as a companion or complementary diagnostic test for six additional tumor types (gastric or gastroesophageal junction adenocarcinoma, cervical cancer, urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), and triple-negative breast carcinoma (TNBC)).